West Cancer Center

PANCREATIC: Metastatic: First-Line: MAPKeeper 301

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)

Title

Immuneering IMM 1104-301 Pancreatic first line

Study Title

Site Link

NCT07562152

Malignancy

Pancreatic, Pancreas

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

1st Line

Investigational Agent

Atebimetinib

Drug Class

MEK inhibitor

Axel Grothey, MD

Sponsor

Immuneering Corporation

Phase

Phase 3

Status

Open to Enrollment

Key Eligibility Criteria

Key Eligibility Criteria Details

Metastatic pancreatic adenocarcinoma within 12 weeks porior to screening
ECOG PS 0-2
No previous systemic anti-cancer therapy
Measurable disease
Cannot have only locally advanced disease
No known active CNS mets

Objective

Primary
- OS
Secondary
- PFS
- ORR
- DCR
- Safety
- QOL

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

Ductal adenocarcinoma

Dosing Frequency

Control Agents

Study Protocol

Randomized

Yes